Z-LVG-CHN2

Category	Herpes simplex Virus (HSV)
CAS	119670-30-3
Description	Z-LVG-CHN2 is a tripeptide derivative that mimics part of the human cysteine proteinase-binding center. Z-LVG-CHN2 effectively blocks SARS-COV-2 replication (EC50 = 190 nM) via inhibition of SARS-COV-2 3CL pro protease.

Quotation Now

Synonyms	L-Valinamide, N-[(phenylmethoxy)carbonyl]-L-leucyl-N-(3-diazo-2-oxopropyl)-(9CI); Z-LVG-DMK
IUPAC Name	benzyl N-[1-[[1-[(3-diazo-2-oxopropyl)amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate
Molecular Weight	445.51
Molecular Formula	C22H31N5O5
Canonical SMILES	CC(C)CC(C(=O)NC(C(C)C)C(=O)NCC(=O)C=[N+]=[N-])NC(=O)OCC1=CC=CC=C1
InChI	InChI=1S/C22H31N5O5/c1-14(2)10-18(26-22(31)32-13-16-8-6-5-7-9-16)20(29)27-19(15(3)4)21(30)24-11-17(28)12-25-23/h5-9,12,14-15,18-19H,10-11,13H2,1-4H3,(H,24,30)(H,26,31)(H,27,29)
InChIKey	KRMMQWXJLDORCJ-UHFFFAOYSA-N
Purity	95%
Solubility	In vitro: 10 mM in DMSO
Appearance	Light yellow to green yellow (Solid)
Storage	Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month
Complexity	697
Exact Mass	445.23251911
In Vitro	Z-LVG-CHN2 (0-10 μM; pre-treated for 16 h) inhibits antiviral activities in a discernable dose-dependent manner in Vero E6 cells by designed to capture multicycle replication, exhibiting an EC50 value of 0.19 μM/ Cell Viability Assay Cell Line: Vero E6 cells Concentration: 0.001 μM, 0.003 μM, 0.1 μM, 0.3 μM, 1 μM, 2.5 μM Incubation Time: Pre-treated for 16 h and then cultured for 24 hours Result: Inhibited SARS-COV-2 virus replication in a dose-dependent manner.
Target	EC50: 190 nM (SAR-COV-2)
XLogP3-AA	3